{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:09:22Z","timestamp":1782932962646,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12793-x","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:56:49Z","timestamp":1770375409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between overexpression of efflux pumps genes Rv0191 and Rv3008 and pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis: a multi-center study"],"prefix":"10.1186","volume":"26","author":[{"given":"Mohammad","family":"Hashemzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadegh","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azar Dokht","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Soleimanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Savari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"12793_CR1","unstructured":"World Health Organization (WHO). Global Tuberculosis Report 2023 Available at http:\/\/www.who.int\/tb\/en."},{"key":"12793_CR2","first-page":"56","volume":"37","author":"SR Moaddab","year":"2015","unstructured":"Moaddab SR, Amini K, Haki. K.Determining the drug susceptibility of Mycobacterium tuberculosis strains to the Pyrazinamide. Med J Tabriz Univ Med Sci. 2015;37:56\u201362.","journal-title":"Med J Tabriz Univ Med Sci"},{"key":"12793_CR3","doi-asserted-by":"publisher","unstructured":"Alavi SM, Enayatrad M, Cheraghian B, Amoori N. Incidence trend analysis of tuberculosis in Khuzestan Province, Southwest of Iran: 2010\u20132019. Glob Epidemiol. 2023;6:100118. https:\/\/doi.org\/10.1016\/j.gloepi.2023.100118.","DOI":"10.1016\/j.gloepi.2023.100118"},{"key":"12793_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-11157-1","volume":"21","author":"B Kiani","year":"2021","unstructured":"Kiani B, Raouf Rahmati A, Bergquist R, Hashtarkhani S, Firouraghi N, Bagheri N, Mohammadi A. Spatio-temporal epidemiology of the tuberculosis incidence rate in Iran 2008 to 2018. BMC Public Health. 2021;21:1\u201320. https:\/\/doi.org\/10.1186\/s12889-021-11157-1.","journal-title":"BMC Public Health"},{"key":"12793_CR5","first-page":"1","volume":"28","author":"EG Tursun","year":"2025","unstructured":"Tursun EG, Bozok T, Aslan G. Antimicrobial resistance mechanisms in non-tuberculous mycobacteria. Folia Microbiol. 2025;28:1\u20130.","journal-title":"Folia Microbiol"},{"issue":"1","key":"12793_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tim.2021.05.001","volume":"30","author":"M Laws","year":"2022","unstructured":"Laws M, Jin P, Rahman KM. Efflux pumps in Mycobacterium tuberculosis and their Inhibition to tackle antimicrobial resistance. Trends Microbiol. 2022;30(1):57\u201368.","journal-title":"Trends Microbiol"},{"key":"12793_CR7","doi-asserted-by":"crossref","unstructured":"Remm S, Earp JC, Dick T, Dartois V, Seeger MA. Critical discussion on drug efflux in Mycobacterium tuberculosis. FEMS Microbiol Rev. 2022;46(1):fuab050.","DOI":"10.1093\/femsre\/fuab050"},{"key":"12793_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3389\/fmicb.2017.00711","volume":"8","author":"D Machado","year":"2017","unstructured":"Machado D, Coelho TS, Perdig\u00e3o J, Pereira C, Couto I, Portugal I, Maschmann RD, Ramos DF, von Groll A, Rossetti ML, Silva PA. Interplay between mutations and efflux in drug resistant clinical isolates of Mycobacterium tuberculosis. Front Microbiol. 2017;8:711.","journal-title":"Front Microbiol"},{"key":"12793_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14787210.2020.1760845","volume":"18","author":"L Rodrigues","year":"2020","unstructured":"Rodrigues L, Cravo P, Viveiros M. Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs. Expert Rev Anti Infect Ther. 2020;18:741\u201357. https:\/\/doi.org\/10.1080\/14787210.2020.1760845.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"12793_CR10","doi-asserted-by":"publisher","unstructured":"Pitaloka DAE, Arfan A, Ramadhan DSF, Chaidir L. Insights from the molecular mechanism of pyrazinamide to mutated pyrazinamidase linked to the pncA gene in clinical isolates of Mycobacterium tuberculosis. J Biomol Struct Dyn. 2024;42, 759\u2013765. 2023:1\u20137. https:\/\/doi.org\/10.1080\/07391102.2023.2195002.","DOI":"10.1080\/07391102.2023.2195002"},{"key":"12793_CR11","doi-asserted-by":"publisher","first-page":"100959","DOI":"10.1016\/j.drup.2023.100959","volume":"68","author":"SJ Modlin","year":"2023","unstructured":"Modlin SJ, Mansj\u00f6 M, Werngren J, Ejike CM, Hoffner SE, Valafar F. Pyrazinamide-resistant tuberculosis is obscured from common targeted molecular diagnostics. Drug Resist Updat. 2023;68:100959. https:\/\/doi.org\/10.1016\/j.drup.2023.100959.","journal-title":"Drug Resist Updat"},{"issue":"9","key":"12793_CR12","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1128\/AAC.00204-15","volume":"59","author":"SM Ramirez-Busby","year":"2015","unstructured":"Ramirez-Busby SM, Valafar F. Systematic review of mutations in Pyrazinamidase associated with Pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2015;59(9):5267\u201377.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"12793_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/microorganisms13061306","volume":"13","author":"M Chimal-Mu\u00f1oz","year":"2025","unstructured":"Chimal-Mu\u00f1oz M, P\u00e9rez-Mart\u00ednez DE, Berm\u00fadez Hern\u00e1ndez GA, Mej\u00eda-Ponce PM, Licona-Cassani C, Mu\u00f1iz-Salazar R, Montero H, Zenteno-Cuevas R. Whole-Genome sequence analysis to assess mutations in efflux pumps in Mycobacterium tuberculosis: the influence in drug resistance. Microorganisms. 2025;13(6):1306.","journal-title":"Microorganisms"},{"key":"12793_CR14","unstructured":"Jawetz, Melnick & Adelberg\u2019s Medical Microbiology. 24th ed. Vishal; San Francisco: March 2007. Chapter 24."},{"issue":"2","key":"12793_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.21037\/jtd.2019.01.58","volume":"11","author":"JY Kang","year":"2019","unstructured":"Kang JY, Hur J, Kim S. Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic L\u00f6wenstein-Jensen method for Isoniazid or rifampicin drug susceptibility tests in tuberculosis patients. J Thorac Dis. 2019;11(2):400\u20139.","journal-title":"J Thorac Dis"},{"key":"12793_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.32592\/JSMJ.23.1.44","volume":"23","author":"M Hashemzadeh","year":"2024","unstructured":"Hashemzadeh M, Asareh Zadegan Dezfuli A, Moinikhah M, Yousefi FI. Phenotypic and genotypic resistance to Pyrazinamide antibiotic in multidrug-resistant (MDR) Mycobacterium tuberculosis isolates in Khuzestan Province from 2017 to 2022 Jundishapur scientific. Med J. 2024;23:44\u201360. https:\/\/doi.org\/10.32592\/JSMJ.23.1.44.","journal-title":"Med J"},{"issue":"4","key":"12793_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.30699\/ijmm.18.4.265","volume":"18","author":"A Zia Sheybani","year":"2024","unstructured":"Zia Sheybani A, Hoseinzadeh S, Habibnia S. Molecular diagnosis of Drug-Resistant Mycobacterium tuberculosis isolates using IS6110 gene in tuberculosis patients. Iran J Med Microbiol. 2024;18(4):265\u20139.","journal-title":"Iran J Med Microbiol"},{"issue":"8","key":"12793_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00940-17","volume":"61","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang J, Cui P, Zhang Y, Zhang W. Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008, and Rv1667c involved in Pyrazinamide resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61(8):10\u2013128.","journal-title":"Antimicrob Agents Chemother"},{"key":"12793_CR19","doi-asserted-by":"crossref","unstructured":"Khosravi AD, Sirous M, Absalan Z, Tabandeh MR, Savari MC. Of DrrA and DrrB efflux pump genes expression in drug-susceptible and-resistant Mycobacterium tuberculosis strains isolated from tuberculosis patients. in Iran. Infect Drug Resist. 2019; 3437\u201344.","DOI":"10.2147\/IDR.S221823"},{"issue":"23","key":"12793_CR20","doi-asserted-by":"publisher","first-page":"e25122","DOI":"10.1002\/jcla.25122","volume":"38","author":"N Mohammadnabi","year":"2024","unstructured":"Mohammadnabi N, Shamseddin J, Emadi M, Bodaghi AB, Varseh M, Shariati A, Rezaei M, Dastranj M, Farahani A. Mycobacterium tuberculosis: the mechanism of pathogenicity, immune responses, and diagnostic challenges. J Clin Lab Anal. 2024;38(23):e25122.","journal-title":"J Clin Lab Anal"},{"key":"12793_CR21","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1038\/s41467-021-24127-3","volume":"12","author":"P Santucci","year":"2021","unstructured":"Santucci P, Greenwood DJ, Fearns A, Chen K, Jiang H, Gutierrez MG. Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic Pyrazinamide. Nat Commun. 2021;12:3816. https:\/\/doi.org\/10.1038\/s41467-021-24127-3.","journal-title":"Nat Commun"},{"key":"12793_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.02342-16","volume":"61","author":"M Yee","year":"2017","unstructured":"Yee M, Gopal P, Dick T. Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with Pyrazinamide resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61:10\u20131128. https:\/\/doi.org\/10.1128\/AAC.02342-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"12793_CR23","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1128\/AAC.00654-16","volume":"60","author":"AL Den Hertog","year":"2016","unstructured":"Den Hertog AL, Menting S, Pfelt R, Warns M, Siddiqi SH. Anthony R M Pyrazinamide is active against Mycobacterium tuberculosis cultures at neutral H and low temperature. J Antimicrob Chemother. 2016;60:4956\u201360. https:\/\/doi.org\/10.1128\/AAC.00654-16.","journal-title":"J Antimicrob Chemother"},{"key":"12793_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-016-1533-z","volume":"16","author":"ST Pullan","year":"2016","unstructured":"Pullan ST, Allnutt JC, Devin R, Hatch KA, Jeeves RE, Hendon-Dunn CL. The effect of growth rate on Pyrazinamide activity in Mycobacterium tuberculosis-insights for early bactericidal activity? BMC Infect Dis. 2016;16:1\u201311. https:\/\/doi.org\/10.1186\/s12879-016-1533-z.","journal-title":"BMC Infect Dis"},{"key":"12793_CR25","doi-asserted-by":"publisher","unstructured":"Gonzalo X, Drobniewski F, Hoffner S, Werngren J. Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis. J Antimicrob Chemother. 2014 69, 3001\u20133005. https:\/\/doi.org\/10.1093\/jac\/dku230.","DOI":"10.1093\/jac\/dku230"},{"key":"12793_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1590\/s1806-37132012000500013","volume":"38","author":"LS Fonseca","year":"2012","unstructured":"Fonseca LS, Marsico AG, Vieira G B D O, Duarte RDS, Saad MHF, Mello. F D C Q.Correlation between resistance to Pyrazinamide and resistance to other antituberculosis drugs in Mycobacterium tuberculosis strains isolated at a referral hospital. J Bras Pneumol. 2012;38:630\u20133. https:\/\/doi.org\/10.1590\/s1806-37132012000500013.","journal-title":"J Bras Pneumol"},{"key":"12793_CR27","doi-asserted-by":"publisher","first-page":"679","DOI":"10.5588\/ijtld.14.0768","volume":"19","author":"AK Alame-Emane","year":"2015","unstructured":"Alame-Emane AK, Xu P, Pierre-Audigier C, Cadet-Daniel V, Shen X, Sraouia M, Gicquel B. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. Int J Tuberc Lung Dis. 2015;19:679\u201384. https:\/\/doi.org\/10.5588\/ijtld.14.0768.","journal-title":"Int J Tuberc Lung Dis"},{"key":"12793_CR28","doi-asserted-by":"crossref","unstructured":"Nasr\u2011Esfahani B, Moghim S, Salehi M, Keikha M. Evaluating the frequency of resistance to pyrazinamide among drug\u2011resistant strains of Mycobacterium tuberculosis in Isfahan, Iran. Arch Clin Infect Dis. 2021;16(2):e101092.","DOI":"10.5812\/archcid.101092"},{"key":"12793_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/cid\/cit452","volume":"57","author":"EV Kurbatova","year":"2013","unstructured":"Kurbatova EV, Cavanaugh JS, Dalton T, Click S, Cegielski E. Epidemiology of pyrazinamide-resistant tuberculosis in the united States, 1999\u20132009. Clin Infect Dis. 2013;57:1081\u201393. https:\/\/doi.org\/10.1093\/cid\/cit452.","journal-title":"Clin Infect Dis"},{"key":"12793_CR30","doi-asserted-by":"publisher","unstructured":"Liu B, Su P, Hu P, Yan M, Li W, Yi S, Tan YP. Transmission and genetic diversity of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Hunan, China. Infect Drug Resist. 2024;403\u201316. https:\/\/doi.org\/10.2147\/IDR.S436161.","DOI":"10.2147\/IDR.S436161"},{"key":"12793_CR31","doi-asserted-by":"crossref","unstructured":"Tamilzhalagan S, Justin ES, Selvaraj A, Venkateswaran K, Sivakumar AK, Chittibabu S, McLaughlin HP, Moonan PK, Smith JP, Suba S, Sathya Narayanan MK. Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance\u2014India, 2018\u20132020. Front Microbiol. 2025 15:1515627.","DOI":"10.3389\/fmicb.2024.1515627"},{"key":"12793_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5530\/jyp.2024.16.21","volume":"17","author":"Y Pang","year":"2017","unstructured":"Pang Y, Zhu D, Zheng H, Shen J, Hu Y, Liu J, Zhao Y. Prevalence and molecular characterization of Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17:1\u20138. https:\/\/doi.org\/10.5530\/jyp.2024.16.21.","journal-title":"BMC Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12793-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:48:37Z","timestamp":1773146917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12793-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12793"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12793-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the Helsinki Declaration. Following the submission of the preliminary proposal, the study received approval from the Institutional Ethics and Review Board of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, and the necessary permission for sample collection was granted (IR.AJUMS.MEDICINE.REC.1400.001). Written informed consent was obtained from all participants. After the preliminary proposal was submitted, permission to collect the sample was granted. The Tuberculosis Center Data Protection Authority also approved the study. All respondents were provided with an information letter about the study and asked to give written consent to participate. We made it clear that participation was voluntary and that individuals could withdraw from the study at any time. Furthermore, all procedures involving human participants confirmed that written consent had been obtained for the use of their information. In this study, personal information such as names, surnames, ethnicity, and personal identification numbers, as well as any information participants requested remain unpublished, was excluded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"528"}}